Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 18 de 18
Filtrer
1.
Neurotox Res ; 32(3): 362-367, 2017 Oct.
Article de Anglais | MEDLINE | ID: mdl-28478529

RÉSUMÉ

Alpha-synuclein (SNCA) oligomers have been reported to inhibit autophagy. Aminochrome-induced SNCA oligomers are neurotoxic, but the flavoenzyme DT-diaphorase prevents both their formation and their neurotoxicity. However, the possible protective role of DT-diaphorase against autophagy impairment by aminochrome-induced SNCA oligomers remains unclear. To test this idea, we used the cell line RCSN-3NQ7SNCA, with constitutive expression of a siRNA against DT-diaphorase and overexpression SNCA, and RCSN-3 as control cells. A significant increase in LC3-II expression was observed in RCSN-3 cells treated with 20 µM aminochrome and 10 µM rapamycin followed by a decrease in cell death compared to RCSN-3 cells incubated with 20 µM aminochrome alone. The incubation of RCSN-3NQ7SNCA cells with 20 µM aminochrome and 10 µM rapamycin does not change the expression of LC3-II in comparison with RCSN-3NQ7SNCA cells incubated with 20 µM aminochrome alone. The incubation of both cell lines preincubated with 100 nM bafilomycin and 20 µM aminochrome increases the level of LC3-II. Under the same conditions, cell death increases in both cell lines in comparison with cells incubated with 20 µM aminochrome. These results support the protective role of DT-diaphorase against SNCA oligomers-induced autophagy inhibition.


Sujet(s)
Autophagie/physiologie , Indolequinones/toxicité , NADPH dehydrogenase (quinone)/métabolisme , Dégénérescence nerveuse/induit chimiquement , Neuroprotection/physiologie , alpha-Synucléine/métabolisme , Animaux , Autophagie/effets des médicaments et des substances chimiques , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/physiologie , Expression des gènes/effets des médicaments et des substances chimiques , Cellules HEK293 , Humains , Macrolides/toxicité , Protéines associées aux microtubules/métabolisme , NADPH dehydrogenase (quinone)/génétique , Dégénérescence nerveuse/enzymologie , Neuroprotection/effets des médicaments et des substances chimiques , Petit ARN interférent , Rats , Sirolimus/toxicité , alpha-Synucléine/génétique
2.
Mol Neurobiol ; 54(6): 4795-4805, 2017 08.
Article de Anglais | MEDLINE | ID: mdl-27510504

RÉSUMÉ

Patients affected by glutaric aciduria type I (GA-I) show progressive cortical leukoencephalopathy whose pathogenesis is poorly known. In the present work, we exposed cortical astrocytes of wild-type (Gcdh +/+ ) and glutaryl-CoA dehydrogenase knockout (Gcdh -/- ) mice to the oxidative stress inducer menadione and measured mitochondrial bioenergetics, redox homeostasis, and cell viability. Mitochondrial function (MTT and JC1-mitochondrial membrane potential assays), redox homeostasis (DCFH oxidation, nitrate and nitrite production, GSH concentrations and activities of the antioxidant enzymes SOD and GPx), and cell death (propidium iodide incorporation) were evaluated in primary cortical astrocyte cultures of Gcdh +/+ and Gcdh -/- mice unstimulated and stimulated by menadione. We also measured the pro-inflammatory response (TNFα levels, IL1-ß and NF-ƙB) in unstimulated astrocytes obtained from these mice. Gcdh -/- mice astrocytes were more vulnerable to menadione-induced oxidative stress (decreased GSH concentrations and altered activities of the antioxidant enzymes), mitochondrial dysfunction (decrease of MTT reduction and JC1 values), and cell death as compared with Gcdh +/+ astrocytes. A higher inflammatory response (TNFα, IL1-ß and NF-ƙB) was also observed in Gcdh -/- mice astrocytes. These data indicate a higher susceptibility of Gcdh -/- cortical astrocytes to oxidative stress and mitochondrial dysfunction, probably leading to cell death. It is presumed that these pathomechanisms may contribute to the cortical leukodystrophy observed in GA-I patients.


Sujet(s)
Aminoacidopathies congénitales/anatomopathologie , Astrocytes/anatomopathologie , Encéphalopathies métaboliques/anatomopathologie , Cortex cérébral/anatomopathologie , Glutaryl-CoA dehydrogenase/déficit , Mitochondries/métabolisme , Dégénérescence nerveuse/anatomopathologie , Stress oxydatif/effets des médicaments et des substances chimiques , Ménadione/toxicité , Aminoacidopathies congénitales/enzymologie , Animaux , Antioxydants/métabolisme , Astrocytes/effets des médicaments et des substances chimiques , Encéphalopathies métaboliques/enzymologie , Mort cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Fluorescéines/métabolisme , Glutathione peroxidase/métabolisme , Médiateurs de l'inflammation/métabolisme , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiques , Souris , Mitochondries/effets des médicaments et des substances chimiques , Dégénérescence nerveuse/enzymologie , Monoxyde d'azote/métabolisme , Oxydoréduction , Espèces réactives de l'oxygène/métabolisme , Superoxide dismutase/métabolisme
3.
Neurology ; 81(18): 1611-6, 2013 Oct 29.
Article de Anglais | MEDLINE | ID: mdl-24078735

RÉSUMÉ

OBJECTIVE: We investigated dopaminergic and cholinergic correlates of gait speed in Parkinson disease (PD) and non-PD control subjects to test the hypothesis that gait dysfunction in PD may result from multisystem degeneration. METHODS: This was a cross-sectional study. Subjects with PD but without dementia (n = 125, age 65.6 ± 7.3 years) and elderly subjects without PD (n = 32, age 66.0 ± 10.6 years) underwent [¹¹C]dihydrotetrabenazine dopaminergic and [(11)C]methyl-4-piperidinyl propionate acetylcholinesterase PET imaging, and cognitive and clinical testing, including an 8.5-m walk in the dopaminergic "off" state. The fifth percentile of cortical cholinergic activity in the elderly without PD was used to define normal-range activity in the subjects with PD. RESULTS: Normal-range cortical cholinergic activity was present in 87 subjects with PD (69.6%). Analysis of covariance using gait speed as the dependent variable demonstrated a significant model (F = 6.70, p < 0.0001) with a significant group effect (F = 3.36, p = 0.037) and significant slower gait speed in the low cholinergic PD subgroup (0.97 ± 0.22 m/s) with no significant difference between the normal-range cholinergic PD subgroup (1.12 ± 0.20 m/s) and control subjects (1.17 ± 0.18 m/s). Covariate effects were significant for cognition (F = 6.58, p = 0.011), but not for striatal dopaminergic innervation, sex, or age. CONCLUSION: Comorbid cortical cholinergic denervation is a more robust marker of slowing of gait in PD than nigrostriatal denervation alone. Gait speed is not significantly slower than normal in subjects with PD with relatively isolated nigrostriatal denervation.


Sujet(s)
Acetylcholinesterase/métabolisme , Troubles neurologiques de la marche/étiologie , Dégénérescence nerveuse/complications , Dégénérescence nerveuse/enzymologie , Maladie de Parkinson/complications , Maladie de Parkinson/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Analyse de variance , Isotopes du carbone , Cortex cérébral/imagerie diagnostique , Cortex cérébral/anatomopathologie , Troubles de la cognition/diagnostic , Troubles de la cognition/étiologie , Études transversales , Dioxolanes , Femelle , Troubles neurologiques de la marche/imagerie diagnostique , Humains , Mâle , Adulte d'âge moyen , Tests neuropsychologiques , Maladie de Parkinson/imagerie diagnostique , Tomographie par émission de positons , Tétrabénazine/analogues et dérivés , Transporteurs vésiculaires des monoamines/métabolisme
4.
Oxid Med Cell Longev ; 2013: 157857, 2013.
Article de Anglais | MEDLINE | ID: mdl-24379900

RÉSUMÉ

Several lines of investigation have implicated oxidative stress in Parkinson's disease (PD) pathogenesis, but the mechanisms involved are still unclear. In this study, we characterized the involvement of NADPH oxidase (Nox), a multisubunit enzyme that catalyzes the reduction of oxygen, in the 6-hydroxydopamine- (6-OHDA-) induced PD mice model and compared for the first time the effects of this neurotoxin in mice lacking gp91(phox-/-), the catalytic subunit of Nox2, and pharmacological inhibition of Nox with apocynin. Six-OHDA induced increased protein expression of p47(phox), a Nox subunit, in striatum. gp91(phox-/-) mice appear to be completely protected from dopaminergic cell loss, whereas the apocynin treatment conferred only a limited neuroprotection. Wt mice treated with apocynin and gp91(phox-/-) mice both exhibited ameliorated apomorphine-induced rotational behavior. The microglial activation observed within the striatum and the substantia nigra pars compacta (SNpc) of 6-OHDA-injected Wt mice was prevented by apocynin treatment and was not detected in gp91(phox-/-) mice. Apocynin was not able to attenuate astrocyte activation in SN. The results support a role for Nox2 in the 6-OHDA-induced degeneration of dopaminergic neurons and glial cell activation in the nigrostriatal pathway and reveal that no comparable 6-OHDA effects were observed between apocynin-treated and gp91(phox-/-) mice groups.


Sujet(s)
Neurones dopaminergiques/enzymologie , Neurones dopaminergiques/anatomopathologie , Glycoprotéines membranaires/métabolisme , NADPH oxidase/métabolisme , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/anatomopathologie , Maladie de Parkinson/enzymologie , Maladie de Parkinson/anatomopathologie , Animaux , Apomorphine , Antigènes CD11b/métabolisme , Activation enzymatique , Protéine gliofibrillaire acide/métabolisme , Immunohistochimie , Souris , Souris de lignée C57BL , NADPH Oxidase 2 , Néostriatum/enzymologie , Néostriatum/anatomopathologie , Oxidopamine , Substantia nigra/enzymologie , Substantia nigra/anatomopathologie , Tyrosine 3-monooxygenase/métabolisme
5.
Neurosci Lett ; 484(3): 187-91, 2010 Nov 05.
Article de Anglais | MEDLINE | ID: mdl-20732386

RÉSUMÉ

Reactive oxygen species (ROS) appear to be involved in several neurodegenerative disorders. We tested the hypothesis that oxidative stress could have a role in the hippocampal neurodegeneration observed in temporal lobe epilepsy induced by pilocarpine. We first determined the spatio-temporal pattern of ROS generation, by means of detection with dihydroethidium oxidation, in the CA1 and CA3 areas and the dentate gyrus of the dorsal hippocampus during status epilepticus induced by pilocarpine. Fluoro-Jade B assays were also performed to detect degenerating neurons. ROS generation was increased in CA1, CA3 and the dentate gyrus after pilocarpine-induced seizures, which was accompanied by marked cell death. Treatment of rats with a NADPH oxidase inhibitor (apocynin) for 7 days prior to induction of status epilepticus was effective in decreasing both ROS production (by an average of 20%) and neurodegeneration (by an average of 61%). These results suggest an involvement of ROS generated by NADPH oxidase in neuronal death in the pilocarpine model of epilepsy.


Sujet(s)
Épilepsie temporale/métabolisme , Hippocampe/métabolisme , NADPH oxidase/métabolisme , Dégénérescence nerveuse/métabolisme , Pilocarpine/toxicité , Espèces réactives de l'oxygène/métabolisme , Animaux , Mort cellulaire/physiologie , Convulsivants/toxicité , Modèles animaux de maladie humaine , Épilepsie temporale/enzymologie , Épilepsie temporale/anatomopathologie , Hippocampe/anatomopathologie , Mâle , NADPH oxidase/physiologie , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/anatomopathologie , Rats , Rat Wistar , Espèces réactives de l'oxygène/toxicité , Lobe temporal/enzymologie , Lobe temporal/métabolisme , Lobe temporal/anatomopathologie
6.
J Neurosci Methods ; 177(2): 317-21, 2009 Mar 15.
Article de Anglais | MEDLINE | ID: mdl-19026686

RÉSUMÉ

The administration of 6-hydroxydopamine (6-OHDA) into the nigrostriatal pathway is a rat model of Parkinson's disease (PD). The footfault test is a behavioural task in which rodents have their motor functions assessed. Here, we observed that unilaterally 6-OHDA-lesioned animals show a context-induced ipsilateral rotational behaviour when placed on the footfault apparatus for 3 min and this may be used as index to detect lesioned animals. Our results showed a sensitivity and specificity of 100% for lesions higher than 94% and 64%, respectively (ROC curve: AUC=0.988). A binary logistic regression model showed an expB=1.116 (95% CI, 1.007-1.236) and C=-9.081+/-4.554 (p=0.046) using the nigral tyrosine hidroxylase immunocontent as standard (each unit represents a 10%-lesion extension). Additionally, the footfault test was more sensitive than apomorphine challenging at 1mg/kg when these tests were carried out days apart and it was less sensitive than methylphenidate at 40 mg/kg (sign test, p<0.05). Therefore, the footfault test may be very useful in the PD animal model for screening animals since it is fast and simple and it does not require a drug to induce rotational activity.


Sujet(s)
Sciences du comportement/méthodes , Neuropharmacologie/méthodes , Oxidopamine/toxicité , Syndromes parkinsoniens/diagnostic , Syndromes parkinsoniens/physiopathologie , Animaux , Comportement animal/effets des médicaments et des substances chimiques , Comportement animal/physiologie , Sciences du comportement/instrumentation , Modèles animaux de maladie humaine , Dopamine/biosynthèse , Agonistes de la dopamine/pharmacologie , Évaluation préclinique de médicament/instrumentation , Évaluation préclinique de médicament/méthodes , Démarche/effets des médicaments et des substances chimiques , Démarche/physiologie , Troubles neurologiques de la marche/induit chimiquement , Troubles neurologiques de la marche/diagnostic , Troubles neurologiques de la marche/physiopathologie , Mâle , Dégénérescence nerveuse/induit chimiquement , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/anatomopathologie , Neurones/effets des médicaments et des substances chimiques , Neurones/enzymologie , Neurones/anatomopathologie , Neuropharmacologie/instrumentation , Syndromes parkinsoniens/induit chimiquement , Rats , Rat Wistar , Substantia nigra/effets des médicaments et des substances chimiques , Substantia nigra/enzymologie , Substantia nigra/anatomopathologie , Sympatholytiques/toxicité , Tyrosine 3-monooxygenase/effets des médicaments et des substances chimiques , Tyrosine 3-monooxygenase/métabolisme
7.
Brain Res ; 1221: 134-40, 2008 Jul 24.
Article de Anglais | MEDLINE | ID: mdl-18554575

RÉSUMÉ

Glutamate is the main excitatory neurotransmitter in brain involved in pathophysiology of several brain injuries. In this context, glutamate showed to stimulate ecto-nucleotidase activities in cerebellar granule cells increasing extracellular adenosine levels, an important neuromodulator in the CNS able to prevent cell damage. The organoselenium compounds, such as ebselen and diphenyl diselenide [(PhSe)(2)], display neuroprotective activities mediated at least in part by their antioxidant and anti-inflammatory properties. Ebselen was described to prevent glutamate-induced lipid peroxidation and cell death in cerebellar granule cells and (PhSe)(2) modify glutamatergic synapse parameters in vitro and in vivo. In the present study, we investigated the effects of ebselen or (PhSe)(2) on glutamate-induced stimulation of ecto-nucleotidase activities in rat cultured cerebellar granule cells. Glutamate increased nucleotide hydrolysis at lower concentrations (10 and 100 microM) than described in the literature and this effect was counteracted by both organoselenium compounds tested. Based on these results, we investigated the association of organoselenium effects with their antioxidant properties searching for redox site modulation by using the alkylant agent N-ethylmaleimide (NEM). Our results suggest that selenium compounds, as well as the well-known antioxidant trolox, can avoid the increase on glutamate-induced stimulation of ecto-nucleotidase activities probably due to their antioxidant properties.


Sujet(s)
Adenosine triphosphatases/effets des médicaments et des substances chimiques , Souffrance cérébrale chronique/traitement médicamenteux , Dégénérescence nerveuse/traitement médicamenteux , Neurones/effets des médicaments et des substances chimiques , Neuroprotecteurs/pharmacologie , Sélénium/pharmacologie , Adenosine triphosphatases/métabolisme , Animaux , Antioxydants/pharmacologie , Azoles/pharmacologie , Souffrance cérébrale chronique/enzymologie , Souffrance cérébrale chronique/physiopathologie , Cellules cultivées , Cervelet/cytologie , Cervelet/effets des médicaments et des substances chimiques , Cervelet/métabolisme , Chromanes/pharmacologie , Relation dose-effet des médicaments , Antienzymes/pharmacologie , N-Éthyl-maléimide/pharmacologie , Acide glutamique/métabolisme , Isoindoles , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/physiopathologie , Neurones/enzymologie , Neuroprotecteurs/métabolisme , Nucléotides/métabolisme , Composés organiques du sélénium/pharmacologie , Stress oxydatif/effets des médicaments et des substances chimiques , Stress oxydatif/physiologie , Rats , Sélénium/métabolisme
8.
J Neurosci ; 28(16): 4115-22, 2008 Apr 16.
Article de Anglais | MEDLINE | ID: mdl-18417691

RÉSUMÉ

Mitochondrial dysfunction and oxidative stress contribute to motor neuron degeneration in amyotrophic lateral sclerosis (ALS). Recent reports indicate that astrocytes expressing the mutations of superoxide dismutase-1 (SOD1) may contribute to motor neuron injury in ALS. Here, we provide evidence that mitochondrial dysfunction in SOD1(G93A) rat astrocytes causes astrocytes to induce apoptosis of motor neurons. Mitochondria from SOD1(G93A) rat astrocytes displayed a defective respiratory function, including decreased oxygen consumption, lack of ADP-dependent respiratory control, and decreased membrane potential. Protein 3-nitrotyrosine was detected immunochemically in mitochondrial proteins from SOD1(G93A) astrocytes, suggesting that mitochondrial defects were associated with nitroxidative damage. Furthermore, superoxide radical formation in mitochondria was increased in SOD1(G93A) astrocytes. Similar defects were found in mitochondria isolated from the spinal cord of SOD1(G93A) rats, and pretreatment of animals with the spin trap 5,5-dimethyl-1-pyrroline N-oxide restored mitochondrial function, forming adducts with mitochondrial proteins in vivo. As shown previously, SOD1(G93A) astrocytes induced death of motor neurons in cocultures, compared with nontransgenic ones. This behavior was recapitulated when nontransgenic astrocytes were treated with mitochondrial inhibitors. Remarkably, motor neuron loss was prevented by preincubation of SOD1(G93A) astrocytes with antioxidants and nitric oxide synthase inhibitors. In particular, low concentrations (approximately 10 nm) of two mitochondrial-targeted antioxidants, ubiquinone and carboxy-proxyl nitroxide, each covalently coupled to a triphenylphosphonium cation (Mito-Q and Mito-CP, respectively), prevented mitochondrial dysfunction, reduced superoxide production in SOD1(G93A) astrocytes, and restored motor neuron survival. Together, our results indicate that mitochondrial dysfunction in astrocytes critically influences motor neuron survival and support the potential pharmacological utility of mitochondrial-targeted antioxidants in ALS treatment.


Sujet(s)
Antioxydants/administration et posologie , Astrocytes/enzymologie , Mitochondries/enzymologie , Motoneurones/enzymologie , Dégénérescence nerveuse/enzymologie , Superoxide dismutase/génétique , Substitution d'acide aminé/génétique , Sclérose latérale amyotrophique/métabolisme , Sclérose latérale amyotrophique/anatomopathologie , Sclérose latérale amyotrophique/prévention et contrôle , Animaux , Animal génétiquement modifié , Astrocytes/effets des médicaments et des substances chimiques , Astrocytes/anatomopathologie , Cellules cultivées , Systèmes de délivrance de médicaments/méthodes , Mitochondries/effets des médicaments et des substances chimiques , Mitochondries/métabolisme , Motoneurones/effets des médicaments et des substances chimiques , Motoneurones/anatomopathologie , Dégénérescence nerveuse/génétique , Dégénérescence nerveuse/prévention et contrôle , Rats , Rat Sprague-Dawley , Superoxide dismutase/physiologie
9.
Neurosci Lett ; 434(1): 139-43, 2008 Mar 21.
Article de Anglais | MEDLINE | ID: mdl-18304734

RÉSUMÉ

Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.


Sujet(s)
Antioxydants/pharmacologie , Encéphalopathies métaboliques/traitement médicamenteux , Encéphale/effets des médicaments et des substances chimiques , Creatine kinase/antagonistes et inhibiteurs , Stress oxydatif/effets des médicaments et des substances chimiques , Urémie/traitement médicamenteux , Acétylcystéine/pharmacologie , Acétylcystéine/usage thérapeutique , Animaux , Antioxydants/usage thérapeutique , Encéphale/enzymologie , Encéphale/physiopathologie , Encéphalopathies métaboliques/enzymologie , Encéphalopathies métaboliques/physiopathologie , Creatine kinase/métabolisme , Déferoxamine/pharmacologie , Déferoxamine/usage thérapeutique , Régulation négative/effets des médicaments et des substances chimiques , Régulation négative/physiologie , Ischémie/complications , Maladies du rein/complications , Mâle , Dégénérescence nerveuse/traitement médicamenteux , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/physiopathologie , Stress oxydatif/physiologie , Rats , Rat Wistar , Fractions subcellulaires , Facteurs temps , Résultat thérapeutique , Urémie/enzymologie , Urémie/physiopathologie
10.
J Neurochem ; 102(3): 723-30, 2007 Aug.
Article de Anglais | MEDLINE | ID: mdl-17437548

RÉSUMÉ

It has been shown that nicotine prevents the loss of dopamine (DA) in the corpus striatum (CS) after 6-hydroxydopamine injection in the substantia nigra. To study the role of the enzyme tyrosine hydroxylase (TH; EC 1.14.16.2) in this experimental paradigm, we have examined its activity by assessing the accumulation of l-3,4-dihydroxyphenylalanine after inhibiting the subsequent enzyme in the DA synthetic pathway, aromatic l-amino acid decarboxylase, with 3-hydroxybenzylhydrazine. In addition the amount of TH protein was assessed by western blotting and its distribution in the CS was examined using immunohistochemical methods. 6-hydroxydopamine injection produced a significant decrease in DA levels and l-3,4-dihydroxyphenylalanine accumulation, as well as decreases in TH protein and TH immunoreactive fibres in the CS. After nicotine treatment, the decrease in TH protein in the CS was significantly reduced, with a concomitant preservation of TH activity, but nicotine did not alter the number of TH immunoreactive fibres. The activity and amount of TH did not change in the contralateral (intact) CS. Thus, nicotine induces long lasting TH plasticity in the degenerating CS. A synergistic action of nicotine-activated and lesion-originated signals appears necessary for the expression of this neuronal molecular plasticity.


Sujet(s)
Corps strié/effets des médicaments et des substances chimiques , Dégénérescence nerveuse/traitement médicamenteux , Plasticité neuronale/effets des médicaments et des substances chimiques , Nicotine/pharmacologie , Tyrosine 3-monooxygenase/métabolisme , Animaux , Inhibiteurs de la décarboxylase des acides aminés aromatiques , Aromatic-L-amino-acide decarboxylases/métabolisme , Axones/effets des médicaments et des substances chimiques , Axones/enzymologie , Corps strié/enzymologie , Corps strié/physiopathologie , Dénervation , Dopamine/métabolisme , Régulation négative/effets des médicaments et des substances chimiques , Régulation négative/physiologie , Lévodopa/métabolisme , Mâle , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/physiopathologie , Plasticité neuronale/physiologie , Nicotine/usage thérapeutique , Agonistes nicotiniques/pharmacologie , Agonistes nicotiniques/usage thérapeutique , Oxidopamine , Syndromes parkinsoniens/traitement médicamenteux , Syndromes parkinsoniens/métabolisme , Syndromes parkinsoniens/physiopathologie , Rats , Rat Sprague-Dawley
11.
Neurochem Int ; 46(5): 391-7, 2005 Apr.
Article de Anglais | MEDLINE | ID: mdl-15737437

RÉSUMÉ

Cystinosis is a disorder associated with lysosomal cystine accumulation caused by defective cystine efflux. Cystine accumulation provokes a variable degree of symptoms depending on the involved tissues. Adult patients may present brain cortical atrophy. However, the mechanisms by which cystine is toxic to the tissues are not fully understood. Considering that brain damage may be developed by energy deficiency, creatine kinase is a thiolic enzyme crucial for energy homeostasis, and disulfides like cystine may alter thiolic enzymes by thiol/disulfide exchange, the main objective of the present study was to investigate the effect of cystine on creatine kinase activity in total homogenate, cytosolic and mitochondrial fractions of the brain cortex from 21-day-old Wistar rats. We performed kinetic studies and investigated the effects of GSH, a biologically occurring thiol group protector, and cysteamine, the drug used for cystinosis treatment, to better understand the effect of cystine on creatine kinase activity. Results showed that cystine inhibited the enzyme activity non-competitively in a dose- and time-dependent way. GSH partially prevented and reversed CK inhibition caused by cystine and cysteamine fully prevented and reversed this inhibition, suggesting that cystine inhibits creatine kinase activity by interaction with the sulfhydryl groups of the enzyme. Considering that creatine kinase is a crucial enzyme for brain cortex energy homeostasis, these results provide a possible mechanism for cystine toxicity and also a new possible beneficial effect for the use of cysteamine in cystinotic patients.


Sujet(s)
Cortex cérébral/effets des médicaments et des substances chimiques , Cortex cérébral/enzymologie , Creatine kinase/antagonistes et inhibiteurs , Mercaptamine/pharmacologie , Cystine/pharmacologie , ADP/composition chimique , Animaux , Fixation compétitive/effets des médicaments et des substances chimiques , Creatine kinase/métabolisme , Cystinose/complications , Cystinose/enzymologie , Cytosol/effets des médicaments et des substances chimiques , Cytosol/enzymologie , Relation dose-effet des médicaments , Activation enzymatique/effets des médicaments et des substances chimiques , Antienzymes/pharmacologie , Glutathion/pharmacologie , Mitochondries/effets des médicaments et des substances chimiques , Mitochondries/enzymologie , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/étiologie , Phosphocréatine/composition chimique , Rats , Rat Wistar , Fractions subcellulaires/effets des médicaments et des substances chimiques , Fractions subcellulaires/enzymologie
12.
Neurotoxicol Teratol ; 26(6): 817-23, 2004.
Article de Anglais | MEDLINE | ID: mdl-15451045

RÉSUMÉ

Methylmercury (MeHg) is a well-known environmental pollutant toxic to the nervous tissue, particularly during development. We recently described transitory hippocampal changes in neonate rats prenatally exposed to MeHg. In this study, we evaluate oxidative stress in the hippocampus on the 1st and 30th postnatal days. Motor behavior (open-field, foot-fault and strength tests) of these animals also was studied after the 30th postnatal day. Female Wistar rats were injected with MeHg (5 mg/Hg/day) on the 12th, 13th and 14th gestational days. Biochemical parameters measured for oxidative stress were levels of the antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT). Total antioxidant reactivity (TAR) and protein oxidation (contents of tryptophan and tyrosine) were also recorded. Our results showed low activities of antioxidant enzymes in the MeHg group at birth. SOD activity remained reduced on the 30th postnatal day. Moreover, a decrease of TAR and protein oxidation was observed only at 30 days of age. No changes were observed in the motor behavior of these animals. Although mercury content in hippocampus is present at undetectable levels at 30 days of age, we observed more persistent changes in oxidative balance. Our data confirm that mercury induces oxidative stress in hippocampus and that this alteration, particularly SOD activity, remained altered even when mercury was no longer present.


Sujet(s)
Antioxydants/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Composés méthylés du mercure/toxicité , Stress oxydatif/effets des médicaments et des substances chimiques , Effets différés de l'exposition prénatale à des facteurs de risque , Facteurs âges , Animaux , Animaux nouveau-nés , Catalase/effets des médicaments et des substances chimiques , Catalase/métabolisme , Modèles animaux de maladie humaine , Régulation négative/effets des médicaments et des substances chimiques , Régulation négative/physiologie , Femelle , Glutathione peroxidase/effets des médicaments et des substances chimiques , Glutathione peroxidase/métabolisme , Hippocampe/croissance et développement , Activité motrice/effets des médicaments et des substances chimiques , Dégénérescence nerveuse/induit chimiquement , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/physiopathologie , Neurotoxines/toxicité , Stress oxydatif/physiologie , Grossesse , Rats , Rat Wistar , Superoxide dismutase/effets des médicaments et des substances chimiques , Superoxide dismutase/métabolisme , Tryptophane/métabolisme , Tyrosine/métabolisme
13.
J Neurosci Res ; 77(3): 410-9, 2004 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-15248297

RÉSUMÉ

The ultrastructural change that characterizes the onset of Wallerian degeneration is the disintegration of axoplasmic microtubules and neurofilaments, which are converted into an amorphous and granular material, followed by myelin breakdown. The mechanism underlying such processes is an increase in the amount of intracellular calcium, leading to activation of proteases called calpains. The aim of this study was to evaluate by quantitative ultrastructural analysis whether nerve fibers can be preserved by the use of an exogenous inhibitor of these proteases (calpain inhibitor-2, Mu-F-hF-FMK), after optic nerve crush. For that, the left optic nerves of opossums, Didelphis aurita, were crushed with the aid of a fine forceps, and half of them received a calpain inhibitor mixed with Elvax resin. Ninety-six hours after the lesion, the animals were reanesthetized and transcardially perfused, and the optic nerves were removed, the right ones being used as normal nerves. Afterward, the optic nerves were dissected and processed for routine transmission electron microscopy and quantitative and statistical analysis. The results of this analysis showed that the group that received the calpain inhibitor presented a reduction of astrogliosis, maintaining the optic nerve structure in an organized state; a significant decrease in the number of degenerating fibers; and a significant increase in the number of fibers with preserved cytoskeleton and preservation of axonal and myelin area and integrity, reducing the enlargement and edema of the axon. In conclusion, our findings suggest that calpain inhibitor is able to provide neuroprotection of the central nervous system fibers after a crush lesion.


Sujet(s)
Axones/effets des médicaments et des substances chimiques , Calpain/antagonistes et inhibiteurs , Inhibiteurs de la cystéine protéinase/pharmacologie , Dégénérescence nerveuse/prévention et contrôle , Neurofibres myélinisées/effets des médicaments et des substances chimiques , Oligopeptides/pharmacologie , Nerf optique/effets des médicaments et des substances chimiques , Animaux , Axones/enzymologie , Axones/ultrastructure , Inhibiteurs de la cystéine protéinase/usage thérapeutique , Écrasement de nerf/méthodes , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/anatomopathologie , Neurofibres myélinisées/enzymologie , Neurofibres myélinisées/ultrastructure , Oligopeptides/usage thérapeutique , Opossum , Nerf optique/enzymologie , Nerf optique/ultrastructure
14.
Neurosci Lett ; 357(1): 49-52, 2004 Feb 26.
Article de Anglais | MEDLINE | ID: mdl-15036611

RÉSUMÉ

Nitric oxide is generated from l-arginine by a family of three distinct nitric oxide synthase (NOS) enzymes playing a crucial role in the physiopathology of spinal cord injury (SCI). Cyclosporin-A (CsA), an immunosupressive agent, may be used to inhibit the activity of iNOS and perhaps to protect against neural tissue destruction. Rats were submitted to SCI by contusion, and killed 4, 24 and 72 h after lesion. Results showed an increase in the activity of iNOS at 72 h after the SCI, inhibited by CsA (2.5 mg/kg) administered 12 h after trauma. iNOS Western blot assay showed an increase in the expression of iNOS after trauma, also antagonized by CsA administration.


Sujet(s)
Ciclosporine/pharmacologie , Dégénérescence nerveuse/traitement médicamenteux , Dégénérescence nerveuse/prévention et contrôle , Nitric oxide synthase/antagonistes et inhibiteurs , Monoxyde d'azote/biosynthèse , Traumatismes de la moelle épinière/traitement médicamenteux , Animaux , Modèles animaux de maladie humaine , Femelle , Protéines I-kappa B/effets des médicaments et des substances chimiques , Protéines I-kappa B/métabolisme , Immunosuppresseurs/pharmacologie , Facteur de transcription NF-kappa B/effets des médicaments et des substances chimiques , Facteur de transcription NF-kappa B/métabolisme , Dégénérescence nerveuse/enzymologie , Nitric oxide synthase/métabolisme , Nitric oxide synthase type II , Rats , Rat Wistar , Traumatismes de la moelle épinière/enzymologie , Traumatismes de la moelle épinière/physiopathologie , Transcription génétique/effets des médicaments et des substances chimiques , Transcription génétique/physiologie
15.
Cell Mol Neurobiol ; 22(3): 289-301, 2002 Jun.
Article de Anglais | MEDLINE | ID: mdl-12469871

RÉSUMÉ

1. Previous work demonstrated that estradiol (E2) treatment prevented the abnormal response to stress and the reduction of glucocorticoid receptors (GR) in hippocampus from aging male rats. The mechanisms originating these effects were unknown. 2. In the present work, we investigated the E2 effects on the cholinergic, growth-associated protein (GAP-43) expressing neurons of the medial septum (MS) and vertical limb of diagonal band of Broca (VDB). These areas project to the hippocampus, and may be involved in the mentioned E2 effects in aging animals. Therefore, the response to E2 of choline-acetyltransferase (ChAT) in neurons and cell processes and GAP-43 mRNA as a marker of neurite outgrowth was studied in young and old male rats. 3. Young (3-4 months) and old (18-20 months) male Sprague-Dawley rats remained untreated or were implanted s.c. with a 14 mg pellet of E2 benzoate during 6 weeks. We used immoucytochemistry to determine ChAT and isotopic in situ hybridization to analyze GAP-43 mRNA expression. 4. Aging males showed a reduction in the number and length of ChAT-immunoreactive cell processes, but not in the number of positive neurons in MS and VDB. E2 reverted both parameters in old rats to levels of young animals. Regarding basal levels of GAP-43 mRNA, they were similar in old and young animals, but E2 treatment up-regulated GAP-43 mRNA expression in MS and VDB of old animals only. 5. Our data suggest that prolonged E2 treatment may affect hippocampal function of aging male rats by regulating in part the plasticity of cholinergic, GAP-43 expressing neurones of the basal forebrain. Without discarding a direct E2 effect on the limbic tissue, effects on the cholinergic system may have a pronounced impact on the neuroendocrine and stress responses of the aging hippocampus.


Sujet(s)
Vieillissement/effets des médicaments et des substances chimiques , Choline O-acetyltransferase/métabolisme , Oestrogènes/pharmacologie , Protéine GAP-43/génétique , Dégénérescence nerveuse/traitement médicamenteux , Neuroprotecteurs/pharmacologie , Télencéphale/effets des médicaments et des substances chimiques , Vieillissement/métabolisme , Vieillissement/anatomopathologie , Animaux , Neurofibres cholinergiques/effets des médicaments et des substances chimiques , Neurofibres cholinergiques/enzymologie , Neurofibres cholinergiques/anatomopathologie , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/enzymologie , Hippocampe/physiopathologie , Immunohistochimie , Mâle , Dégénérescence nerveuse/enzymologie , Dégénérescence nerveuse/physiopathologie , Voies nerveuses/effets des médicaments et des substances chimiques , Voies nerveuses/enzymologie , Voies nerveuses/physiopathologie , Neurones/effets des médicaments et des substances chimiques , Neurones/enzymologie , Neurones/anatomopathologie , ARN messager/métabolisme , Rats , Rat Sprague-Dawley , Noyaux du septum/effets des médicaments et des substances chimiques , Noyaux du septum/enzymologie , Noyaux du septum/physiopathologie , Télencéphale/enzymologie , Télencéphale/physiopathologie
16.
Neuroscience ; 106(4): 669-77, 2001.
Article de Anglais | MEDLINE | ID: mdl-11682154

RÉSUMÉ

Impairment of glutamate uptake or the reverse action of its transporters has been suggested as the mechanism responsible for the increased glutamate extracellular levels associated with ischemic neuronal damage. In previous studies we have shown that glutamate uptake inhibition by L-trans-pyrrolidine-2,4-dicarboxylate (PDC) in the rat striatum and hippocampus in vivo does not induce neuronal death despite the notable increase in the extracellular levels of glutamate and aspartate. However, PDC intracerebral administration leads to neuronal death in rats chronically injected with the mitochondrial toxin 3-nitropropionic acid (3-NP), an inhibitor of succinate dehydrogenase (SDH). In the present study we have determined the time course of inhibition of SDH activity in the striatum of rats acutely injected with a single dose of 3-NP (20 mg/kg), and studied its relation to PDC neurotoxicity. PDC induced larger lesions when administered during maximum inhibition of SDH activity while smaller lesions were found when it was injected during recovery of enzyme activity. We also studied the neuroprotective effect of different energy substrates such as creatine, pyruvate, and the ketone bodies beta-hydroxybutyrate and acetoacetate in this experimental model. Our results show partial protection with all compounds except for beta-hydroxybutyrate that showed no protection, while MK-801 completely prevented PDC-induced neuronal damage. We believe that the present results might be of relevance for the understanding of the mechanisms responsible for ischemic neuronal death and its prevention.


Sujet(s)
Système X-AG de transport d'acides aminés/métabolisme , Encéphalopathie ischémique/enzymologie , Métabolisme énergétique/physiologie , Dégénérescence nerveuse/enzymologie , Neuroprotecteurs/pharmacologie , Neurotoxines/pharmacologie , Succinate Dehydrogenase/métabolisme , Acide 3-hydroxy-butyrique/pharmacologie , Acétoacétates/pharmacologie , Système X-AG de transport d'acides aminés/antagonistes et inhibiteurs , Animaux , Encéphalopathie ischémique/physiopathologie , Convulsivants/pharmacologie , Créatine/pharmacologie , Diacides carboxyliques/pharmacologie , Interactions médicamenteuses/physiologie , Métabolisme énergétique/effets des médicaments et des substances chimiques , Antagonistes des acides aminés excitateurs/pharmacologie , Acide glutamique/métabolisme , Mâle , Néostriatum/effets des médicaments et des substances chimiques , Néostriatum/enzymologie , Néostriatum/physiopathologie , Dégénérescence nerveuse/physiopathologie , Neurones/effets des médicaments et des substances chimiques , Neurones/enzymologie , Inhibiteurs de la capture des neurotransmetteurs/pharmacologie , Composés nitrés , Propionates/pharmacologie , Pyrrolidines/pharmacologie , Acide pyruvique/pharmacologie , Rats , Rat Wistar , Succinate Dehydrogenase/antagonistes et inhibiteurs
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE